To Get more Insights,  Request A Free Sample 

Market Dynamics 

Driver: Aging Population and Increasing Prevalence of Age-Related Macular Degeneration (AMD)

One of the major drivers of the global Age-related Macular Degeneration market is the aging population worldwide. With advancements in healthcare and improvements in living conditions, the global population is experiencing a significant increase in life expectancy. According to the World Health Organization (WHO), the global population of people aged 60 years and older is expected to reach 2 billion by 2050. As individuals age, the risk of developing AMD significantly increases, leading to a higher prevalence of the condition.

The Centers for Disease Control and Prevention (CDC) estimates that approximately 1.8 million people in the United States alone have AMD, and this number is projected to increase to nearly 3 million by 2020. Furthermore, the prevalence of AMD is expected to rise due to the aging population and the increasing prevalence of chronic diseases such as diabetes, which is a risk factor for AMD.

This demographic shift and the associated increase in the prevalence of AMD are driving the demand for effective treatments, diagnostic tools, and therapies, thereby fueling the growth of the global Age-related macular degeneration market. Pharmaceutical companies and healthcare providers are focusing on developing innovative treatments and investing in research and development to address the growing burden of AMD.

Technological Advancements and Innovation in AMD Diagnosis and Treatment

Another significant driver of the global Age-related Macular Degeneration (AMD) market is the continuous technological advancements and innovation in the diagnosis and treatment of AMD. The development of advanced imaging techniques, such as optical coherence tomography (OCT) and fundus autofluorescence (FAF), has revolutionized the early detection and diagnosis of AMD. These imaging techniques enable healthcare professionals to identify and monitor the progression of the disease with high precision.

Additionally, the emergence of innovative therapies, such as anti-vascular endothelial growth factor (anti-VEGF) drugs, has revolutionized the treatment landscape for age-related macular degeneration market. These drugs have shown promising results in slowing down the progression of the disease and preserving vision in patients with neovascular AMD.

According to the World Health Organization (WHO), advancements in technology have the potential to reduce the global burden of vision impairment, including AMD. Early diagnosis and prompt treatment can significantly improve patient outcomes and quality of life. These advancements have fueled the growth of the global Age-related macular degeneration market by creating a favorable environment for the development and adoption of new treatment options and diagnostic tools.

Moreover, ongoing research and development activities are focusing on gene therapies, regenerative medicine, and other novel approaches, which hold great promise for future management in the global age-related macular degeneration market.

Restraint: High Cost of AMD Treatment and Limited Access to Healthcare

Despite the significant drivers propelling the global Age-related Macular Degeneration (AMD) market, a major restraint is the high cost of AMD treatment and limited access to healthcare, particularly in developing countries. The cost of AMD treatments, such as anti-VEGF drugs, can be substantial, especially when considering the need for repeated injections over an extended period.

The World Health Organization (WHO) emphasizes that access to affordable and quality healthcare services is crucial for effective management of chronic conditions like AMD. Unfortunately, many individuals, particularly those in low- and middle-income countries, face financial constraints and lack access to adequate healthcare infrastructure. This leads to delayed diagnosis, limited treatment options, and suboptimal management of AMD.

Moreover, the high cost of advanced diagnostic tools and technologies for AMD screening and monitoring further exacerbates the access barrier. These technologies are often concentrated in urban areas or specialized healthcare centers, making them inaccessible to individuals in remote or underserved regions in the age-related macular degeneration market.

Addressing the issue of affordability and improving access to AMD treatments and healthcare services are vital challenges that need to be overcome to ensure equitable management of AMD globally. Collaboration between governments, healthcare providers, and pharmaceutical companies is necessary to develop strategies that promote affordability, increase awareness, and enhance access to treatment options for all individuals affected by AMD.

Segmental Analysis 

Product Type 

Eylea (aflibercept), a drug marketed by Regeneron Pharmaceuticals, has emerged as a significant contributor to the global Age-Related Macular Degeneration market, accounting for more than 51.73% of the revenue. This signifies a dominant market share and positions Eylea as a leading treatment option for AMD.

Several factors have contributed to Eylea's success. Firstly, clinical trials have demonstrated the drug's efficacy in treating both wet AMD and diabetic macular edema, which has expanded its usage among healthcare providers. Secondly, its favorable dosing schedule requiring less frequent injections compared to other drugs has improved patient compliance.

The substantial age-related macular degeneration market share of Eylea underscores the significant role of innovation in the pharmaceutical industry. However, the market dominance also raises questions about the level of competition and diversity in AMD treatment options. As such, ongoing research and development in this space remain crucial to address these concerns and ensure better outcomes for AMD patients.

Disease Type

Wet AMD accounts for over 90% of revenue of the global age-related macular degeneration market, making it the most common type of the disease worldwide. However, estimates suggest that dry AMD constitutes approximately 85-90% of all AMD cases globally, with its prevalence increasing with age. The high prevalence of dry AMD underscores the need for effective management and treatment options to address the growing burden of the disease.

Currently, there are limited treatment options specifically approved for dry AMD. Nutritional supplements, such as vitamins and minerals, have shown some efficacy in reducing the risk of advanced dry AMD. 

Several factors contribute to the dominance of dry AMD in the global market. The slow progression and milder visual impairment associated with dry AMD result in a larger pool of patients seeking management options compared to the more severe wet AMD. Wet AMD often develops as a progression from dry AMD, highlighting the importance of addressing the dry form to prevent further deterioration. Apart from this, the lack of approved treatments specifically targeting dry AMD directs research and development efforts toward this area. Pharmaceutical companies and researchers are actively exploring innovative solutions to address the unmet medical needs of patients with dry AMD.

By End Users 

The global age-related macular degeneration (AMD) market continues to grow, primarily driven by an aging population and increasing prevalence of AMD. Hospital pharmacies constitute a vital part of this market, contributing more than 52% to the global AMD revenue. This dominance can be attributed to a variety of factors, including accessibility to a wide range of AMD drugs, comprehensive healthcare professional consultations, and streamlined prescription handling procedures.

Furthermore, hospital pharmacies in the age-related macular degeneration market often have a close link with clinics or hospitals, enabling swift and efficient patient diagnosis, treatment, and medication access. These institutions also generally have greater storage and supply chain capacities, allowing them to maintain a broader range of treatments for varying degrees of AMD.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

Age-related macular degeneration (AMD) is a leading cause of blindness worldwide, and its prevalence varies across regions. Surprisingly, North America exhibits a significantly higher prevalence of AMD compared to other regions, sparking research to understand the underlying factors. Recent studies have shed light on two prominent risk factors associated with AMD in North America: smoking and obesity. The findings reveal a 43% increased risk of AMD in smokers and a 37% increased risk in individuals with obesity, aligning with previous research highlighting these lifestyle factors as major contributors to AMD risk.

The reasons behind this higher prevalence in North America age-related macular degeneration market are not entirely clear, but it is speculated that the higher prevalence of smoking and obesity in this region plays a role. Conversely, the study also uncovered that a higher intake of fruits and vegetables was associated with a reduced risk of AMD, likely due to the presence of antioxidants and beneficial nutrients.

Notably, the United States exhibits the highest prevalence of AMD globally, with over 8% of Americans aged 50 and older affected, compared to lower rates in Europeans and East Asians. This high prevalence is attributed to various factors, including genetics, diet, smoking, and exposure to ultraviolet light.

In the United States, AMD is a leading cause of vision loss, particularly among whites. Projections indicate a significant rise in AMD cases by 2050, with an estimated 2.07 million to 5.44 million affected Americans. The study also reveals a higher prevalence of AMD in the United States than in any other country, with approximately 15% of Americans over the age of 50 affected, in contrast to lower rates in Europeans.

Competitive Landscape of Global Age-Related Macular Degeneration Market 

• Novartis: Known for their anti-VEGF drug Lucentis (ranibizumab), which is widely used for AMD treatment.
• Roche/Genentech: Developers of Avastin (bevacizumab), often used off-label for AMD, and Eylea (aflibercept).
• Regeneron Pharmaceuticals: This company developed Eylea (aflibercept), a commonly prescribed drug for AMD.
• Bayer: Partnered with Regeneron to market Eylea outside the United States.
• Allergan (now part of AbbVie): Known for its involvement in eye health, including research into treatments for AMD.
• Pfizer: Has been involved in research for new treatments for AMD.
• Iveric bio: They are developing a complement inhibitor (Zimura) for geographic atrophy secondary to dry AMD.
• Apellis Pharmaceuticals: They have a drug candidate (pegcetacoplan) undergoing clinical trials for geographic atrophy, a severe form of AMD.
• Graybug Vision: Working on long-acting treatments for wet AMD.
• Kodiak Sciences: Known for developing KSI-301, an antibody biopolymer conjugate for the treatment of retinal vascular diseases including wet AMD.
• Alimera Sciences: The company specializes in the commercialization and development of prescription ophthalmic pharmaceuticals.
• Santen Pharmaceutical: A specialized company in ophthalmology, researching and developing solutions for diseases like AMD.

Recent Developments:

• August 2008: Regeneron Pharmaceuticals and Bayer HealthCare reported that patients with wet age-related macular degeneration (AMD) showed significant improvements at 52 weeks in both primary and key secondary endpoints of retinal thickness and vision gain. This data came from a Phase 2 extension study on a PRN (as needed) dosing schedule with the VEGF Trap-Eye, emphasizing the potential for this therapy in treating AMD.
• December 2014: Lpath, in consultation with Pfizer, reported the successful evaluation of iSONEP™ in patients with wet age-related macular degeneration (AMD) in a clinical study. This positive evaluation underscored the potential of iSONEP™ as a viable treatment option for AMD patients.
• October 2019: Novartis announced that the FDA had approved its Beovu® injection for the treatment of wet age-related macular degeneration (AMD). This marked a significant milestone in providing more treatment options for patients with this common condition.
• February 2023: Regeneron Pharmaceuticals revealed that the FDA had accepted its Priority Review of the Biologics License Application (BLA) for Aflibercept 8 mg. The drug is intended to treat wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy. The Priority Review designation signaled that the FDA recognized the potential significance of this drug in addressing unmet medical needs.
• June 2023: F. Hoffmann-La Roche reported that its OpRegen was in Phase 2 clinical development for dry (atrophic) macular degeneration. The advancement into Phase 2 illustrated the potential promise of this treatment for patients suffering from the dry form of AMD, a condition currently lacking effective treatments.

Market Segmentation Overview:

By Product Type

• Eylea
• Lucentis
• Beovu

By Disease Type

• Wet AMD
• Dry AMD

By End Users

• Hospital Pharmacies
• Pharmacies
• Specialty Clinics
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America